Arcturus Therapeutics Holdings Inc. (ARCT)Healthcare | Biotechnology | San Diego, United States | NasdaqGM
11.27 USD
+0.15
(1.349%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 7:03 a.m. EDT
The investment case here is fundamentally broken. Despite a 'strong buy' analyst consensus driven by a lofty $41 price target, the company is hemorrhaging value with -89% revenue growth, negative gross margins, and a return on equity of -46%. The balance sheet is fragile with significant debt relative to equity, and the stock has suffered two consecutive years of decline, capping any potential recovery thesis. The options market confirms this pessimism, with traders aggressively buying deep out-of-the-money puts to hedge against further drops. There is no dividend to provide income, and the recent price action shows no momentum to counteract the deteriorating business metrics. This is a classic value trap where the market has correctly priced out the lack of growth and profitability. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.678247 |
| AutoETS | 0.683315 |
| AutoARIMA | 0.683320 |
| AutoTheta | 0.711904 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 22.17 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.050 |
| Excess Kurtosis | -1.46 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 13.348 |
| Revenue per Share | 1.047 |
| Market Cap | 320,328,000 |
| Forward P/E | -3.04 |
| Beta | 2.48 |
| Website | https://arcturusrx.com |
As of Oct. 10, 2026, 7:03 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (3.2k contracts at $10 strike vs negligible call OI). While there is some volume in calls targeting $17.50 and $22.50, the overwhelming capital allocation is in put writing and buying, suggesting a consensus view of continued volatility or decline rather than a breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.45450145 |
| Address1 | 10,285 Science Center Drive |
| All Time High | 188.72 |
| All Time Low | 4.11 |
| Ask | 7.96 |
| Ask Size | 2 |
| Audit Risk | 9 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 678,120 |
| Average Daily Volume3 Month | 935,589 |
| Average Volume | 935,589 |
| Average Volume10Days | 678,120 |
| Beta | 2.483 |
| Bid | 4.43 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | 6.045 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.27 |
| Current Ratio | 5.879 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 11.42 |
| Day Low | 10.6311 |
| Debt To Equity | 13.348 |
| Display Name | Arcturus Therapeutics |
| Dividend Date | 1,510,790,400 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,048,200 |
| Earnings Call Timestamp Start | 1,786,048,200 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,794,254,400 |
| Earnings Timestamp Start | 1,794,254,400 |
| Ebitda | -99,548,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.525 |
| Enterprise To Revenue | 5.168 |
| Enterprise Value | 151,777,984 |
| Eps Current Year | -3.45454 |
| Eps Forward | -3.7028 |
| Eps Trailing Twelve Months | -3.33 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 13.0034 |
| Fifty Day Average Change | -1.7333994 |
| Fifty Day Average Change Percent | -0.13330355 |
| Fifty Two Week Change Percent | -45.450146 |
| Fifty Two Week High | 24.17 |
| Fifty Two Week High Change | -12.9 |
| Fifty Two Week High Change Percent | -0.5337195 |
| Fifty Two Week Low | 5.5 |
| Fifty Two Week Low Change | 5.7700005 |
| Fifty Two Week Low Change Percent | 1.049091 |
| Fifty Two Week Range | 5.5 - 24.17 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,369,229,400,000 |
| Float Shares | 26,153,203 |
| Forward Eps | -3.7028 |
| Forward P E | -3.0436428 |
| Free Cashflow | 19,258,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 106 |
| Fullday Change | 0.12999916 |
| Fullday Change Percent | 1.1534973 |
| Fullday Price | 11.4 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | -1.95502 |
| Gross Profits | -57,415,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07986 |
| Held Percent Institutions | 0.77406996 |
| Implied Shares Outstanding | 28,423,069 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,510,790,400 |
| Last Split Factor | 1:7 |
| Long Business Summary | Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. |
| Long Name | Arcturus Therapeutics Holdings Inc. |
| Market | us_market |
| Market Cap | 320,328,000 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_235062181 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -93,276,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 378,311,048 |
| Number Of Analyst Opinions | 10 |
| Open | 11.0 |
| Operating Cashflow | -72,729,000 |
| Operating Margins | -8.632979 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 858 900 2660 |
| Pre Market Change | 0.12999916 |
| Pre Market Change Percent | 1.1534973 |
| Pre Market Price | 11.4 |
| Pre Market Time | 1,792,139,824 |
| Previous Close | 11.12 |
| Price Eps Current Year | -3.2623737 |
| Price Hint | 2 |
| Price To Book | 1.8643508 |
| Price To Sales Trailing12 Months | 10.907382 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.764 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.38462 |
| Region | US |
| Regular Market Change | 0.150001 |
| Regular Market Change Percent | 1.34893 |
| Regular Market Day High | 11.42 |
| Regular Market Day Low | 10.6311 |
| Regular Market Day Range | 10.6311 - 11.42 |
| Regular Market Open | 11.0 |
| Regular Market Previous Close | 11.12 |
| Regular Market Price | 11.27 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 492,940 |
| Return On Assets | -0.23964001 |
| Return On Equity | -0.46307 |
| Revenue Growth | -0.895 |
| Revenue Per Share | 1.047 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 28,423,069 |
| Shares Percent Shares Out | 0.1892 |
| Shares Short | 5,378,106 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 6,096,901 |
| Short Name | Arcturus Therapeutics Holdings |
| Short Percent Of Float | 0.2354 |
| Short Ratio | 5.88 |
| Source Interval | 15 |
| State | CA |
| Symbol | ARCT |
| Target High Price | 41.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 23.8 |
| Target Median Price | 20.0 |
| Total Cash | 191,483,008 |
| Total Cash Per Share | 6.737 |
| Total Debt | 22,933,000 |
| Total Revenue | 29,368,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.33 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.77615 |
| Two Hundred Day Average Change | 2.4938507 |
| Two Hundred Day Average Change Percent | 0.28416228 |
| Type Disp | Equity |
| Volume | 492,940 |
| Website | https://arcturusrx.com |
| Zip | 92,121 |